Skip to main content
. Author manuscript; available in PMC: 2013 Jan 30.
Published in final edited form as: Pharm Res. 2010 Aug 19;28(2):215–236. doi: 10.1007/s11095-010-0241-4

Figure 2.

Figure 2

CpG-loaded nanoparticles elicit an OVA-specific antitumor response. In brief, B16-OVA or B16 tumors were implanted s.c. in C57BL/6 mice after four immunizations with 50 μg OVA and 100 μg free CpG or NP-bound CpG (n = 5). A, Immunization with OVA and NP-CpG significantly reduced growth of B16-OVA tumors compared to untreated mice (p < 0.03 at all time points from day 6) or to mice treated with OVA alone 0.02 from day 13). No effect of immunization was seen in the wild-type B16 tumors (n.s. at all time points). B, In mice with B16-OVA tumors, immunization with OVA and NP-CpG increased survival times compared with untreated mice (p = 0.009) or to mice treated with OVA alone (p = 0.003). No effect of immunization on survival was seen in the wild-type B16 tumors. Similar results were obtained in two independent experiments. Reprinted with permission from (139) © Springer Inc. (2008).